ClinicalTrials.gov
ClinicalTrials.gov Menu

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France (ECOS FRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01291394
Recruitment Status : Completed
First Posted : February 8, 2011
Last Update Posted : December 26, 2017
Sponsor:
Collaborator:
Merck Serono S.A.S, France
Information provided by (Responsible Party):
Merck KGaA

Brief Summary:
This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in France and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.

Condition or disease Intervention/treatment
Growth Disorders Device: Easypod™

Detailed Description:

Subjects will be enrolled in this observational, multi-center study to assess adherence and treatment outcomes. Parents will provide their written agreement to upload their child's data in the study electronic CRF.

Easypod™ is an electromechanical device that delivers growth hormone and also records injections' date and time. Adherence data will be primarily derived from injections recorded in the Easypod™ device combined with physician data entry of outcome measures (i.e. height & weight). This will allow the establishment of adherence profiles and evaluate the link with subsequent clinical outcomes.

Since this is an observational study, there will be no study-specific clinical interventions and subjects will be treated according to the clinical and laboratory findings as routinely evaluated by the physician. Auxological and laboratory data will be reported prospectively throughout the duration of the study. At baseline, available data can be recorded retrospectively from the subjects' medical file and Easypod™ device Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

• To assess the level of adherence of subjects receiving Saizen® via Easypod™

Secondary Objectives:

  • To describe the impact of adherence on clinical outcomes for subject receiving Saizen® via Easypod™
  • To identify adherence subject profiling
  • To asses the Impact of adherence on insulin-like growth factor-1 (IGF1) ranges/levels

Study Type : Observational
Actual Enrollment : 223 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment
Actual Study Start Date : January 31, 2011
Actual Primary Completion Date : December 31, 2015
Actual Study Completion Date : December 31, 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources


Intervention Details:
    Device: Easypod™
    Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
    Other Name: Somatotropin


Primary Outcome Measures :
  1. Mean percent of recorded adherence [ Time Frame: At least 6 months and up to 5 years ]

Secondary Outcome Measures :
  1. Correlation of adherence and growth outcome (change in height velocity (HV), change in HV-Standard Deviation Score (HV-SDS), change in height-Standard Deviation Score) after each year of Saizen® treatment with Easypod™ [ Time Frame: At least 6 months and up to 5 years ]
  2. Subject adherence profile [ Time Frame: At least 6 months and up to 5 years ]
    Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment, administration regimen (6 or 7 days/ week), combination of pituitary hormone deficiencies, previous and/or concomitant treatments, socio-economic data

  3. Correlation of adherence with IGF-1 levels/ranges [ Time Frame: At least 6 months and up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects who are taking SAIZEN® for a pediatric registered indications using the Easypod™ electromechanical device.
Criteria

Inclusion Criteria:

  • Administered Saizen® via the Easypod™ electromechanical device according to pediatric registered indications (Growth Hormone Deficiency, Small for Gestational Age, Turner-Syndrome or prepubertal children with Chronic Renal Failure).
  • Naïve subjects or already treated with Saizen and Easypod for maximum 1 year
  • Male and Female between 2 - 18 years of age, or over 18 without fusion of growth plates
  • Parent's or guardian's (or subject if over 18 without fusion of growth plates) written agreement, given before entering data into the study, with the understanding that the subject or parent/guardian may withdraw agreement at any time without prejudice to future medical care.

Exclusion Criteria:

  • Subjects taking Saizen® in whom growth plates have fused (i.e. taking growth hormone for it's metabolic effects)
  • Contra-indications to Saizen® as defined in the French Summary of Product Characteristics (SmPC)
  • Use of an investigational drug or participation in an interventional clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01291394


Locations
France
Contact Merck KGaA
Communication Center, France
Sponsors and Collaborators
Merck KGaA
Merck Serono S.A.S, France
Investigators
Study Director: Medical Director MGS Division, Merck Serono s.a.s, France, an affiliate of Merck KGaA, Darmstadt, Germany

Publications of Results:
Koledova, E. et al. (2017) Analysis of results from the global, 5-year Easypod™ Connect Observational Study (ECOS) study in children with growth disorders. 10th International Meeting for Pediatric Endocrinology; 2017 Sep 14-17; Washington, DC.
Wit, JM. et al. (2017) Effect of adherence on the 2-year growth response to growth hormone treatment in prepubertal children with idiopathic isolated growth hormone deficiency participating in the EasypodTM Connect Observational Study (ECOS). 10th International Meeting of Paediatric Endocrinology; 2017 Sep 14-17; Washington, DC.

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT01291394     History of Changes
Other Study ID Numbers: EMR 200104-515
First Posted: February 8, 2011    Key Record Dates
Last Update Posted: December 26, 2017
Last Verified: December 2017

Keywords provided by Merck KGaA:
Growth disorders
Saizen
Easypod
Growth hormone
Pediatric subject

Additional relevant MeSH terms:
Growth Disorders
Pathologic Processes